Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Jim Cramer weighs in on the U.S.-China trade war and Amgen.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Mizuho's Salim Syed says talk of possible tieup isn't far-fetched. Alexion and Amgen decline comment.
Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.
Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.